Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2021-04-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
独立董事述职报告（崔丽晶）
Board/Management Information Classification · 95% confidence The document is titled as the "2020年度独立董事述职报告" (2020 Annual Independent Director's Report) for 葵花药业集团股份有限公司. It contains detailed independent director opinions on various company matters throughout 2020, including attendance at board meetings, independent opinions on appointments, financial and operational matters, internal controls, use of raised funds, guarantees, and other governance-related issues. The document is a comprehensive report by an independent director on their duties and observations for the year 2020. It is not a full annual report (10-K), audit report, or earnings release, but rather a management-related report focusing on governance and oversight activities by an independent director. It is not a short announcement or certification but a substantive report of about 9,592 characters. Therefore, the best fitting category is "Board/Management Information (MANG)" as it relates to management and board oversight information, specifically the independent director's report on their duties and opinions for the year.
2021-04-20 Chinese
东海证券股份有限公司关于葵花药业集团股份有限公司2020年度募集资金存放及使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Donghai Securities Co., Ltd. regarding the 2020 annual verification of the deposit and use of raised funds by Kuihua Pharmaceutical Group Co., Ltd. It includes specifics on the amount of funds raised, their usage, management, and compliance with regulatory requirements. The document references regulatory guidelines such as the Shenzhen Stock Exchange listing rules and includes an auditor's verification report. The content focuses on the management and use of capital raised through stock issuance, with detailed financial figures and compliance statements. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full annual report, audit report, or earnings release, but a specialized report on the use of raised funds, consistent with CAP filings. The document length (7446 characters) and detailed financial data support this classification with high confidence.
2021-04-20 Chinese
2020年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2020年度监事会工作报告" which translates to "2020 Supervisory Board Work Report". It details the supervisory board's activities, including oversight of financial reports, internal controls, information disclosure, and compliance with laws and regulations for the year 2020. The document includes summaries of meetings, opinions on company operations, financial status, internal controls, and plans for 2021. It is a report from the supervisory board rather than a full annual report or audit report. It is not a short announcement or certification but a substantive report on supervisory activities. This fits the category of Management Reports (MDA), which include management's detailed explanation of financial results, business trends, and outlook, as the supervisory board is part of management oversight and provides detailed commentary on company governance and financial supervision.
2021-04-20 Chinese
监事会关于《公司2020年度内部控制自我评价报告》审核意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review opinion on the company's 2020 internal control self-evaluation report. It references laws and regulations and confirms the adequacy of the internal control system. The document is short (430 characters) and appears to be an audit or review opinion rather than the full report itself. It does not contain full financial statements or detailed financial data. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. Therefore, the classification is AR with high confidence. FY 2020
2021-04-20 Chinese
期货套期保值业务管理制度
Regulatory Filings Classification · 95% confidence The document is titled as a management system for futures hedging business of a company, detailing internal control, organizational structure, approval authority, risk management, reporting, and accounting policies related to futures hedging activities. It is a detailed internal policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it an announcement of a report. It is not related to board changes, voting results, or legal proceedings. It is a regulatory compliance and internal control document related to risk management and operational procedures. Such documents do not fit into the specific financial report categories but are regulatory or compliance filings. Therefore, the best fitting category is Regulatory Filings (RNS). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement (RPA).
2021-04-20 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) on non-operating fund occupation and other related party fund transactions for the year 2020 by 葵花药业集团股份有限公司. It includes detailed tables summarizing related party transactions and fund occupation, with references to audited financial statements and regulatory compliance notices from Chinese securities authorities. The document is issued by an accounting firm with audit certification references, indicating it is a standalone audit-related report focusing on specific financial compliance and related party transactions rather than a full annual report or interim report. The length is about 2921 characters, which is relatively short but contains substantive financial data and audit commentary. It is not a mere announcement or certification letter but a special audit report on related party transactions. Therefore, it fits best under Audit Report / Information (AR). FY 2020
2021-04-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.